Bicycle Therapeutics plc Net Assets
Bicycle Therapeutics plc net assets. Based on the latest financial reports, Bicycle Therapeutics plc (50BA) has net assets worth €510.25 Million EUR (≈ $596.54 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€606.58 Million ≈ $709.15 Million USD) and total liabilities (€96.32 Million ≈ $112.61 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Bicycle Therapeutics plc (50BA) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €510.25 Million |
| % of Total Assets | 84.12% |
| Annual Growth Rate | N/A |
| 5-Year Change | 76.16% |
| 10-Year Change | N/A |
| Growth Volatility | 101.17 |
Net Assets of Bicycle Therapeutics plc (2018–2025)
Net assets of Bicycle Therapeutics plc from 2018 to 2025. This chart illustrates how Bicycle Therapeutics plc's net assets have evolved over time, based on quarterly financial data. See Bicycle Therapeutics plc balance sheet independence to measure how much of total assets are equity-financed.
Annual Net Assets for Bicycle Therapeutics plc (2018–2025)
The table below shows the annual net assets of Bicycle Therapeutics plc from 2018 to 2025. For live market cap and overall valuation, see 50BA stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €609.98 Million ≈ $713.13 Million |
-23.09% |
| 2024-12-31 | €793.06 Million ≈ $927.17 Million |
+113.80% |
| 2023-12-31 | €370.93 Million ≈ $433.66 Million |
+36.98% |
| 2022-12-31 | €270.78 Million ≈ $316.57 Million |
-21.80% |
| 2021-12-31 | €346.25 Million ≈ $404.81 Million |
+262.72% |
| 2020-12-31 | €95.46 Million ≈ $111.60 Million |
+2.43% |
| 2019-12-31 | €93.20 Million ≈ $108.96 Million |
+233.47% |
| 2018-12-31 | €-69.83 Million ≈ $-81.63 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bicycle Therapeutics plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 82980900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Bicycle Therapeutics plc Net Assets Breakdown (December 2025)
Bicycle Therapeutics plc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.51 Billion | 247.51% |
| Total Equity | €609.98 Million | 100.00% |
Bicycle Therapeutics plc Competitors by Market Cap
The table below lists competitors of Bicycle Therapeutics plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Goodluck India Limited
NSE:GOODLUCK
|
$184.94 Million |
|
EIH Associated Hotels Limited
NSE:EIHAHOTELS
|
$184.95 Million |
|
Zhejiang Lianxiang Smart Home
SHG:603272
|
$185.00 Million |
|
Lithium Royalty Corp
TO:LIRC
|
$185.06 Million |
|
Bicycle Therapeutics Ltd
NASDAQ:BCYC
|
$184.87 Million |
|
Sunjuice Holdings Co Ltd
TW:1256
|
$184.83 Million |
|
SillaJen Inc
KQ:215600
|
$184.78 Million |
|
Iones Co. Ltd
KQ:114810
|
$184.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bicycle Therapeutics plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 793,060,000 to 609,977,000, a change of -183,083,000 (-23.1%).
- Net loss of 218,960,000 reduced equity.
- Other factors increased equity by 35,877,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-218.96 Million | -35.9% |
| Other Changes | €35.88 Million | +5.88% |
| Total Change | €- | -23.09% |
Book Value vs Market Value Analysis
This analysis compares Bicycle Therapeutics plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.36x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | €-3.95 | €3.14 | x |
| 2019-12-31 | €5.18 | €3.14 | x |
| 2020-12-31 | €4.53 | €3.14 | x |
| 2021-12-31 | €11.71 | €3.14 | x |
| 2022-12-31 | €9.06 | €3.14 | x |
| 2023-12-31 | €8.74 | €3.14 | x |
| 2024-12-31 | €11.48 | €3.14 | x |
| 2025-12-31 | €8.79 | €3.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bicycle Therapeutics plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -301.66%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 1.18x
- Recent ROE (-35.90%) is below the historical average (-31.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -306.14% | 0.09x | 0.00x | €-14.86 Million |
| 2019 | -32.84% | -221.78% | 0.13x | 1.18x | €-39.93 Million |
| 2020 | -53.44% | -490.95% | 0.06x | 1.69x | €-60.56 Million |
| 2021 | -19.30% | -571.25% | 0.02x | 1.39x | €-101.44 Million |
| 2022 | -41.63% | -779.35% | 0.04x | 1.52x | €-139.80 Million |
| 2023 | -48.71% | -669.72% | 0.05x | 1.60x | €-217.76 Million |
| 2024 | -21.31% | -479.18% | 0.04x | 1.21x | €-248.34 Million |
| 2025 | -35.90% | -301.66% | 0.10x | 1.18x | €-279.96 Million |
Industry Comparison
This section compares Bicycle Therapeutics plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $82,275,373
- Average return on equity (ROE) among peers: -15.87%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bicycle Therapeutics plc (50BA) | €510.25 Million | 0.00% | 0.19x | $184.92 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $-294.00K | 0.00% | 0.00x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $141.29 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-223.84 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $230.94 Million | -20.03% | 0.13x | $125.74 Million |
| PreveCeutical Medical Inc (18H) | $-3.60 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $538.39 Million | -12.38% | 0.07x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $218.97 Million | -16.25% | 0.03x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $699.56 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $-852.32K | 0.00% | 0.00x | $960.84K |
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide … Read more